Inhibition of PI3K and MEK: it is all about combinations and biomarkers.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 19584146.
- Also identified by DOI 10.1158/1078-0432.CCR-09-0872.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A small molecule inhibitor of MAP/ERK kinase (MEK) was effective against human breast cancer cells with a basal-like gene expression signature. Antitumor activity was limited by both feedback upregulation of phosphatidylinositol-3 kinase (PI3K)/AKT upon inhibition of MEK as well as loss of the phosphatase PTEN. Therefore, MEK inhibitors should preferably be investigated in combination with PI3K inhibitors in basal-like breast cancers.
Medical subject headings
- Breast Neoplasms
- Enzyme Inhibitors
- MAP Kinase Kinase 1
- Phosphoinositide-3 Kinase Inhibitors
- Xenograft Model Antitumor Assays